Five Star Equities Issues New Research Reports on BRCM, CMTL, EGLE and NAVBadmin
Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Broadcom Corporation (NASDAQ: BRCM) shares gained 2.26 percent to close at $28.51 a share Tuesday. The stock traded between $28.11 and $28.90 on volume 18.24 million shares traded. The company has raised its guidance range for fourth quarter revenues to approximately $2.0 – $2.05 billion. Shares of Broadcom have fallen approximately 14.0 percent year-to-date.
Get more information on Broadcom free access to the in-depth equity report at:
Comtech Telecommunications Corp. (NASDAQ: CMTL) shares gained 2.01 percent to close at $31.92 a share Tuesday. The stock traded between $31.25 and $33.65 on volume of 496,066 shares traded. The company announced that it has raised its annual target dividend from $1.10 per share to $1.20 per share. Shares of Comtech Telecommunications have gained approximately 25.0 percent year-to-date.
Get more information on Comtech and free access to the in-depth equity report at:
Eagle Bulk Shipping Inc. (NASDAQ: EGLE) shares dropped 12.39 percent to close at $3.11 a share Tuesday. The stock traded between $2.78 and $3.25 on volume 3.41 million shares traded. The Wall Street Journal has reported that the company and Genco Shipping & Trading Ltd. have been working with “restructuring advisers after key creditors sold large blocks of debt to distressed investors amid balance sheet concerns.” Shares of Eagle Bulk Shipping have gained approximately 110.0 percent year-to-date.
Get more information on Eagle Bulk Shipping and free access to the in-depth equity report at:
Navidea Biopharmaceuticals Inc. (NYSEMKT: NAVB) shares spiked 12.02 percent to close at $2.05 a share Tuesday. The stock traded between $1.90 and $2.20 on volume 7.29 million shares traded. The company announced that the FDA has granted Fast Track designation to Lymphoseek Injection for sentinel lymph node detection in patients with head and neck cancer. Shares of Navidea Biopharmaceuticals have gained approximately 23.0 percent year-to-date.
Get more information on Navidea Biopharmaceuticals and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities
Posted: December 11th, 2013 under ACCESSWIRE.